Alnylam Pharmaceuticals (ALNY) Shares Fall 29.6% Over the Past Month

Key Takeaways

• Alnylam Pharmaceuticals (ALNY) shares plunged approximately 29.6% over the past 30 days, falling from $312.78 on July 2 to $220.33 as of the latest close on August 3, 2026.
• The primary catalyst was the company's July 30 Q2 2026 earnings report, which featured a $200 million cut to full-year TTR product revenue guidance, triggering a single-day selloff of roughly 28%.
• Earlier in July, the failure of a rival therapy from AstraZeneca — eplontersen in the CARDIO-TTRansform trial — raised concerns about Alnylam's own nucresiran program and contributed to the stock's downward momentum.
• Amvuttra crossed $1 billion in quarterly revenue for the first time, yet management acknowledged that second-line demand growth had normalized faster than expected after an initial wave of pent-up patient transitions.
• Multiple securities law firms launched investigations into whether the company adequately disclosed the pace of its ATTR-CM launch trajectory, while Raymond James upgraded the stock to Strong Buy, citing an attractive risk/reward profile.

Alnylam Pharmaceuticals (ALNY) Company Overview and Market Position

Alnylam Pharmaceuticals is the pioneering leader in RNA interference (RNAi) therapeutics, a field built on Nobel Prize-winning science. Headquartered in Cambridge, Massachusetts, the company has translated over two decades of research into six approved medicines available in more than 70 countries. Its flagship product, Amvuttra (vutrisiran), targets transthyretin-mediated amyloidosis (ATTR) and has become the centerpiece of Alnylam's commercial strategy following its 2025 launch in the broader ATTR cardiomyopathy (ATTR-CM) indication. Alnylam also markets GIVLAARI and OXLUMO for rare genetic diseases, while advancing a deep pipeline spanning Huntington's disease, Alzheimer's, hypertension, and bleeding disorders. Investors closely track ALNY as a high-growth biopharma name with blockbuster revenue potential, balanced against the execution risks inherent in drug launches and clinical trials. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

ALNY Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, ALNY shares experienced a sharp decline of approximately 29.6%, tumbling from a closing price of $312.78 on July 2, 2026, to $220.33 on August 3. The selling was concentrated around two key events: a competitor trial failure in early July that rattled confidence in the broader ATTR silencing approach, and a disappointing Q2 earnings report on July 30 that erased more than 28% of the stock's value in a single session. The quarterly trend paints an equally challenging picture, with the stock extending losses from earlier in 2026. ALNY had already retreated substantially from its 52-week high of $495.55 reached in October 2025, as valuation compression and a March 2026 Jefferies downgrade weighed on sentiment. The July guidance cut accelerated the decline, pushing shares near their 52-week low of $197.81 before a modest bounce into early August.

What Drove ALNY Stock Price in the Last 30 Days

The most consequential event of the past month was Alnylam's second-quarter 2026 earnings release on July 30. While the company posted adjusted earnings per share of $1.84 — beating the $1.60 consensus — total revenue of $1.29 billion missed the $1.32 billion estimate. More critically, management lowered its full-year 2026 TTR product revenue guidance to a range of $4.2 billion to $4.5 billion, down $200 million at the midpoint from its prior forecast of $4.4 billion to $4.7 billion. CFO Jeff Poulton acknowledged that the original guidance "didn't get it right," explaining that early second-line demand growth in 2025 benefited significantly from pent-up demand from patients waiting for a new therapy, a dynamic that normalized sooner than anticipated in 2026. Shares cratered $81.14 to close at $205.48 on July 30. Earlier in the month, the disappointing top-line results from AstraZeneca's CARDIO-TTRansform trial of eplontersen — an antisense oligonucleotide targeting the same TTR pathway — created a volatile trading environment. ALNY initially spiked on the competitive read-through before reversing sharply as investors questioned whether Alnylam's own Phase III TRITON-CM study of nucresiran could face similar headwinds in patients on heavy background therapy. Multiple analyst actions followed: RBC Capital lowered its price target to $350 from $445 while maintaining an Outperform rating; H.C. Wainwright reiterated a Buy rating with a $485 target; and on August 3, Raymond James upgraded ALNY to Strong Buy with a $420 price target, arguing the stock was trading near pessimistic net-present-value levels. Meanwhile, law firms including Kirby McInerney LLP, Bronstein, Gewirtz & Grossman LLC, and Schall, Brown & Schwartz LLP announced securities fraud investigations focused on whether the company adequately disclosed ATTR-CM launch dynamics. From what I see, this combination of factors created significant short-term pressure.

What Drove ALNY Stock Performance Over the Last Quarter

The broader quarterly decline reflects a convergence of multiple headwinds that gradually eroded investor confidence. Alnylam entered the quarter with elevated expectations following a strong 2025 launch of Amvuttra in ATTR-CM, but valuation pressures were already mounting. A March 2026 downgrade from Jefferies — shifting from Buy to Hold with a $330 target — framed the stock as "priced for perfection," and the shares never fully recovered their momentum. A proxy filing in April highlighting substantial performance-tied equity awards added governance-related scrutiny. Against this backdrop, the normalization of second-line patient volumes and the Q2 guidance revision crystallized fears that the ATTR-CM opportunity, while still substantial with roughly 80% of the estimated 200,000-patient population untreated, may require a longer adoption curve than initially modeled. The competitive landscape also evolved: the CARDIO-TTRansform failure removed a potential rival but simultaneously raised the stakes for Alnylam's TRITON-CM trial. On the positive side, Amvuttra continued to demonstrate category-defining metrics — quarterly revenue exceeding $1 billion for the first time, first-line starts accounting for approximately 80% of new patient initiations, and adherence rates above 90%. The delayed U.S. generic entry for Pfizer's tafamidis until mid-2031 also provides a longer competitive runway.

ALNY Stock Forecast Drivers: What Investors Should Watch Next

Looking ahead, several catalysts will shape ALNY's trajectory. The presentation of full CARDIO-TTRansform data and Alnylam's TRITON-CM Phase III enrollment and design updates — particularly at the upcoming European Society of Cardiology congress — will be closely scrutinized for signals about nucresiran's probability of success. Investors will also monitor quarterly TTR prescription trends for evidence that first-line demand growth can offset the normalization in second-line volumes. The company's pipeline milestones, including initial Phase I Huntington's disease data for ALN-HTT02 at EHDN in October and Phase II readouts across the rare disease portfolio, could shift the narrative beyond the TTR franchise. Regulatory developments, the outcome of the securities investigations, and the evolving competitive dynamics in the ATTR-CM market — including Pfizer's entrenched tafamidis position and emerging candidates from Ionis Pharmaceuticals — remain critical variables. Alnylam's $3.3 billion cash position provides substantial financial flexibility, but the path to restoring investor confidence will depend on consistent commercial execution and clinical data that validate the company's RNAi platform beyond its current approved indications. I’m watching this closely as the next data points arrive.

Navigating Market Volatility with AI Assistance

In periods of elevated volatility like the one surrounding ALNY, I often rely on data-driven resources to cross-check my own analysis. Tickeron’s Trending AI Robots offer a useful window into automated strategies that have performed well recently across equities and other assets. These tools help highlight patterns and signals that complement traditional research without replacing independent judgment.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Notable companies

Industry description

Market Cap

High and low price notable news

Volume